Is ZIOP a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,627 people get ZIOP articles and Market Currents by email alert.

Get email alerts on ZIOP »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

OncoSec's And Ziopharm's IL-12 Targeted Delivery Systems: Which Will Succeed?
Chemistfrog • Wed, Jun 12 • 20 Comments
AP Pharma And Ziopharm: The Differences Between Bad News
Alexander Maxwell • Sun, Mar 31 • 10 Comments
Ziopharm: What Now?
Alexander Maxwell • Thu, Mar 28 • 15 Comments
Ziopharm's Palifosfamide Fails Its Soft Tissue Cancer Indication, NSCLC Next?
Brian L. Wilson • Thu, Mar 28 • 7 Comments
Why Retail Got Slaughtered On Ziopharm
Richard Pearson • Wed, Mar 27 • 15 Comments
Ziopharm Offers High Risk, High Return
Todd Johnson • Mon, Mar 18 • 22 Comments
Ziopharm Oncology May Win The Battle But Will They Win The War?
Robert Schwartz • Thu, Mar 14 • 104 Comments
Ziopharm: What Are The Odds Of The Control Group Outperforming?
David Sobek • Thu, Feb 21 • 62 Comments
Ziopharm: What Happens Next?
Zhen Lu • Tue, Feb 19 • 22 Comments
Ziopharm: Key Oncology Catalyst Approaching
PropThink • Mon, Dec 10, 2012 • 6 Comments
Richard Pearson Responds On Ziopharm
Richard Pearson • Fri, Oct 26, 2012 • 85 Comments
Ziopharm Oncology: Completion Of PICASSO 3 Clinical Trial Shows Promises For Driving Stock
LifeSci Advisors • Thu, Aug 23, 2012 • 8 Comments
Ziopharm: A Short Squeeze In The Making?
Wall Street Teacher • Mon, Apr 23, 2012 • 33 Comments
5 Reasons To Buy Ziopharm
Markus Aarnio • Fri, Mar 16, 2012 • 15 Comments
Challenging Targets Could Pay Off For Ziopharm Oncology
Stephen Simpson • Wed, Mar 14, 2012 • 4 Comments
Ziopharm: Small Molecules Meet Next-Generation Synthetic Biology
Wall Street Teacher • Thu, Jun 30, 2011 • 37 Comments
Ziopharm and Intrexon's Odd Coupling
Jason Chew • Mon, Feb 14, 2011 • 5 Comments
Ziopharm Oncology's Global Strategy Provides Potential Upside for Investors
Steven Breazzano • Tue, Jan 18, 2011 • 6 Comments
Ziopharm Oncology: Place Your Bets
Wall Street Teacher • Fri, Aug 27, 2010 • 6 Comments
Ziopharm: The Money's in the Bank, So What's Next?
Wall Street Teacher • Fri, Dec 11, 2009 • 13 Comments

To learn more about Seeking Alpha Pro, click here.

Complete Kyle Bass And Hayman Capital Portfolio Update
Profit Fan • Fri, May 17 • 8 Comments
Threshold: My Biotech Pick Of The Year
Equity Options Guru • Tue, Apr 23 • 17 Comments
3 Biotechs And The Feuerstein-Ratain Rule
Equity Options Guru • Tue, Apr 9 • 32 Comments
Opko: Retail Investors Vs. The Insider Cliff
Richard Pearson • Tue, Apr 9 • 55 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Wed, Mar 27 • 2 Comments
Ziopharm Fails Phase III Trial, Threshold Now The Leader
Equity Options Guru • Tue, Mar 26 • 10 Comments
Threshold Pharmaceuticals - A Derivative Trade On Ziopharm's Upcoming Data
PropThink • Fri, Mar 22 • 26 Comments
2 Biotechs Ready To Fly
Equity Options Guru • Fri, Mar 15 • 8 Comments
Small Pharmas With Imminent Catalysts For March 2013
Chemistfrog • Mon, Mar 11 • 5 Comments
3 Speculative Biotech Companies Looking To Reshape The Healthcare Landscape
A John Hodge • Wed, Mar 6 • 5 Comments
2 Biotech Superstars For 2013
Equity Options Guru • Tue, Mar 5 • 30 Comments
Threshold Pharmaceuticals: A Biotech Trading At Half Its Intrinsic Value
BPD Research • Mon, Mar 4 • 14 Comments
4 Small Cap Biopharmas With Near-Term Catalysts
Scott Matusow • Mon, Feb 11 • 22 Comments
Investments In Novel IL-12 Adminstration Platforms In The Fight Against Cancer
Chemistfrog • Tue, Dec 25, 2012 • 10 Comments
Mid-Week Biopharma Catalyst Trades To Consider
Scott Matusow • Thu, Dec 13, 2012 • 7 Comments
Upcoming Catalysts For 4 Biotech Stocks
LifeSci Advisors • Thu, Dec 6, 2012 • 8 Comments
Insider Buying Trends: Are These Cash-Rich Companies Ready For A Rally?
Kapitall • Tue, Sep 18, 2012 • 6 Comments
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts This Year
Markus Aarnio • Fri, Aug 10, 2012 • 7 Comments
Riding The Ups And Downs Among Biopharmaceutical Companies
A John Hodge • Thu, Aug 9, 2012 • 1 Comment
Insiders Love These 5 Highly Shorted Biotech Stocks
Kapitall • Wed, Aug 8, 2012 • 4 Comments

ZIOPHARM Oncology's CEO Hosts PICASSO 3 Trial Results Conference (Transcript)
Tue, Mar 26 • 3 Comments
ZIOPHARM Oncology's CEO Presents at Barclays Global Healthcare Conference (Transcript)
Wed, Mar 13 • 1 Comment

ZIOPHARM Announces Presentation of Updated Results From Ad-RTS-IL-12 Phase I Study in Advanced Melanoma at the 2013 ASCO Annual Meeting

GlobeNewswire (Jun 1, 2013)
ZIOPHARM Oncology to Present at the Jefferies 2013 Global Healthcare Conference

GlobeNewswire (May 30, 2013)
ZIOPHARM Oncology to Present at the 38th Annual Deutsche Bank Health Care Conference

GlobeNewswire (May 22, 2013)
ZIOPHARM Announces Presentation of Promising Nonclinical and Phase I Study Results of Ad-RTS-IL-12 in Advanced Melanoma at ASGCT 16th Annual Meeting

GlobeNewswire (May 16, 2013)
ZIOPHARM Announces Poster Presentation at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire (May 15, 2013)
ZIOPHARM Announces First Quarter Financial Results and Key Developments

GlobeNewswire (May 7, 2013)
ZIOPHARM Presents Preclinical Data Supporting DNA-Based IL-12 Therapy for Breast Cancer

GlobeNewswire (Apr 9, 2013)
Movers & Shakers: Tuesday’s movers: Netflix jumps to lead S&P 500

at MarketWatch.com (Mar 26, 2013)
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma

GlobeNewswire (Mar 26, 2013)
ZIOPHARM Reports Fourth Quarter and Full Year 2012 Financial Results

GlobeNewswire (Mar 18, 2013)
ZIOPHARM Oncology Initiates Phase 2 Study of Ad-RTS IL-12 and Palifosfamide Combination for Treatment of Advanced Breast Cancer

GlobeNewswire (Mar 11, 2013)
ZIOPHARM Oncology to Present at the Barclays Global Healthcare Conference

GlobeNewswire (Mar 7, 2013)
ZIOPHARM Oncology Announces Initiation of Indiana University-Sponsored Phase 2 Study of Palifosfamide in Recurrent and Incurable Germ Cell (Testicular and Ovarian) Tumors

GlobeNewswire (Mar 6, 2013)
Ziopharm Bulls Bet on Explosive Move

at CNBC.com (Feb 14, 2013)
Phase 3 Trial of ZIOPHARM'S Palifosfamide in First-Line Metastatic Soft Tissue Sarcoma Reaches Target Number of Progression-Free Survival Events

GlobeNewswire (Feb 12, 2013)
ZIOPHARM Oncology to Present at the 15th Annual BIO CEO & Investor Conference

GlobeNewswire (Feb 6, 2013)
ZIOPHARM Oncology to Present at the 31st Annual J.P. Morgan Healthcare Conference

GlobeNewswire (Jan 3, 2013)
ZIOPHARM Oncology to Participate in the 2012 Deutsche Bank BioFEST Conference

GlobeNewswire (Nov 28, 2012)
ZIOPHARM Oncology to Present at the 24th Annual Piper Jaffray Healthcare Conference

GlobeNewswire (Nov 20, 2012)
Independent Data Monitoring Committee Recommends Completion of PICASSO 3 Trial as Conducted for ZIOPHARM's Palifosfamide in First-Line Soft Tissue Sarcoma

GlobeNewswire (Nov 14, 2012)

ZIOP vs. ETF Alternatives

Company Description

Currently, there's no company description for ZIOP.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 31, 4:51 PM Ziopharm Oncology (ZIOP) says that in connection with the ongoing rationalization and restructuring of its business operations, its CFO and Treasurer Jason A. Amello is departing. The company appoints Kevin G. Lafond, its current Corporate Controller, as Chief Accounting Officer and Treasurer and shall also serve as the Company’s principal financial officer from and after June 3, 2013. Shares +0.5% AH. Comment! [Healthcare]
Tuesday, May 28, 12:45 PM Midday top 10 gainers: VRTB +23%. PIP +21%. LSE +20%. CSIQ +19%. HSOL +18%. HYGS +17%. BLDP +16%. OBCI +13%. SVA +14%. UACL +12%.
Midday top 10 Losers: ENOC -19%. FSGI -13%. RSOL -12%. OXBT -12%. HGSH -11%. BDL -10%. CLNT -10%. VIPS -9%. RPI -9%. ZIOP -9%. Comment! [On the Move]
Friday, May 24, 12:45 PM Midday top 10 gainers: OTT +41%. ZIOP +25%. ESMC +18%. DRAM +17%. FCEL +17%. VNDA +17%. TNP +16%. BLDP +14%. BLOX +13%. VRTA +12%.
Midday top 10 Losers: DF -51%. RNIN -29%. ETAK -17%. SHLD -14%. HIHO -14%. HGSH -12%. PLM -11%. ANF -10%. TITN -10%. ARO -10%. 4 Comments [On the Move]
Friday, May 24, 10:33 AM Ziopharm Oncology (ZIOP +39.1%) soars on huge volume. The stock is now up ~68% since Wednesday. Comment! [Healthcare, On the Move]
Thursday, May 16, 7:53 AM Ziopharm (ZIOP) says results from nonclinical and Phase 1 studies show ad-RTS-IL-12 "is clearly a potent immune stimulator with a demonstrated immune mediated effect in melanoma and other cancers." The studies demonstrate that the severe toxicity often associated with the delivery of Il-12 protein can be mediated through a "regulatable gene therapy strategy." A Phase 2 study is underway. The stock (up 1.78% premarket) faces a long road back from a late March collapse triggered by the termination of a Phase 3 trial of palifosfamide. (PR) Comment! [Healthcare]
Tuesday, May 7, 7:30 PM Ziopharm (ZIOP): Q1 EPS of -$0.15 beats by $0.12. Revenue of $200K beats by $40.K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 9, 9:10 AM Premarket gainers: CLRX +13%. ZIOP +12%. RDN +5%. UNXL +5%.
Losers: OCZ -13%. JCP -7%. Comment! [On the Move]
Tuesday, April 9, 8:31 AM Ziopharm's (ZIOP +8.6%) Ad-RTS-mIL-12 DNA-based therapy has demonstrated anti-tumor effects and tolerability in mice. Ad-RTS-IL-12 is being tested in two Phase 2 studies, one for advanced melanoma and the other for breast cancer. (PR) Comment! [Healthcare, On the Move]
Tuesday, March 26, 12:54 PM Midday top 10 gainers: PTEK +30%. BVX +23%. OPXA +20%. LEDS +20%. IBCP +13%. DXYN +11%. GTAT +11%. APP +11%. HGSH +9%. PGNX +9%.
Midday top 10 losers: ZIOP -62%. FUQI -17%. GMAN -16%. PGTI -14%. STSI -13%. GMXR -11%. STXS -11%. PRTS -10%. REED -10%. CSUN -8%. Comment! [On the Move]
Tuesday, March 26, 11:23 AM Threshold Pharmaceuticals (THLD +1.3%) gains on the back of Ziopharm's (ZIOP -63%) earlier announcement that it's ending Phase 3 trials of palifosfamide after it failed to meet its primary endpoint. An article posted in Seeking Alpha last Friday infers that THLD's competing drug, TH-302, although similar to palifosfamide in molecular structure, is differentiated enough in nature that there is still sufficient reason to believe it could work. Now, with ZIOP's drug out of the running, TH-302's addressable market increases significantly. The company is due to release data from its own Phase III study early next year. 1 Comment [Healthcare, On the Move]
Tuesday, March 26, 9:15 AM Premarket gainers: THLD +8%. CTIC +6%.
Losers: ZIOP -62%. PLCE -6%. PATH -6%. Comment! [On the Move]
Tuesday, March 26, 7:17 AM Ziopharm Oncology (ZIOP) -59% after reporting the failure of palifosfamide in its Phase 3 trial, and saying it is pulling development of the treatment. Kudos to Adam Feurstein's source who was certain enough of the test results to short the stock last week. 3 Comments [Healthcare, On the Move]
Friday, March 22, 9:54 AM Ziopharm Oncology (ZIOP -5.8%) opens down big after Adam Feurstein reports an oft-correct source has shorted the stock ahead of what he/she thinks will be the failure of next week's results of the palifosfamide sarcoma study. Comment! [Healthcare, On the Move]
Friday, March 22, 9:10 AM Premarket gainers: HALO +23%. ANAC +18%. MU +9%. AFFY +8%. NKE +8%.
Losers: TIBX -16%. ABR -6%. ZIOP -5%. Comment! [On the Move]
Monday, March 18, 4:49 PM More on Ziopharm (ZIOP): Q4 comes in-line on revenue but misses on a per shares basis. Operating expenses rose 134% over the prior year, primarily due to an $18.7M non-cash expense associated with the issuance of approximately 3.6M shares of common stock to Intrexon as a milestone payment associated with the dosing of the first patient in its Ad-RTS IL-12 Phase 2 trial. Shares -2% AH. Comment! [Healthcare, Earnings, On the Move]
Monday, March 18, 4:22 PM Ziopharm (ZIOP): Q4 EPS of -$0.37 misses by $0.08. Revenue of $200K beats by $30K. Shares -1.1% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]

NIRVANA27
Strong buy $ZIOP
May 28, 4:48 PM
Reply (1)

• !Report Abuse
View all 1 replies
Perkins Cove: My worst trade of the year. Hope you know what you're doing......
May 28, 5:14 PM
• !Report Abuse
Add a reply...

140 characters

dindin21
$ZIOP Could this be a Intrexon takeover announcement? Really interesting.........
May 24, 8:08 PM
Reply (1)

• !Report Abuse
View all 1 replies
Barney: Short squeeze.
May 25, 7:15 AM
• !Report Abuse
Add a reply...

140 characters

StockConsultant
$ZIOP breakout watch above 1.88 and into large price gap http://bit.ly/11YDAne
May 22, 1:26 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it.
Mar 29, 5:26 AM
Reply (3)

• !Report Abuse
View all 3 replies
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
Mar 29, 5:18 PM
• !Report Abuse
yourmama6799: Rashar for President!!!
Mar 29, 6:43 PM
• !Report Abuse
Add a reply...

140 characters

Chris DeMuth Jr.
$ZIOP @ new 52-week low this week
Mar 28, 10:27 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chris DeMuth Jr.
$ZIOP @ new 52-week low
Mar 26, 5:46 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

dindin21
$ZIOP How low do we go? I am guessing $1.50
Mar 26, 4:38 PM
Reply (5)

• !Report Abuse
View all 5 replies
NIRVANA27: why low? im positive - > Strong buy, Bye.
May 28, 4:48 PM
• !Report Abuse
Chris DeMuth Jr.: What do you think it is worth?
May 28, 6:15 PM
• !Report Abuse
Add a reply...

140 characters

Red Acre Investments
While we wait for $ZIOP results - visit Red Acre Investments & cast your vote on which way the data will go: http://bit.ly/14k2VHo
Mar 25, 6:50 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Red Acre Investments
In case you're not already reading us at redacre.com - here's our take on $ZIOP: http://bit.ly/16uPEeQ
Mar 14, 12:54 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

SKS1586
Sold $ZIOP to keep >20% profit & create CASH for better opportunities
Mar 1, 11:37 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

dindin21
$ZIOP How low do we go? I am guessing $1.50
Mar 26, 4:38 PM
Reply (5)

• !Report Abuse
View all 5 replies
NIRVANA27: why low? im positive - > Strong buy, Bye.
May 28, 4:48 PM
• !Report Abuse
Chris DeMuth Jr.: What do you think it is worth?
May 28, 6:15 PM
• !Report Abuse
Add a reply...

140 characters

NIRVANA27
Strong buy $ZIOP
May 28, 4:48 PM
Reply (1)

• !Report Abuse
View all 1 replies
Perkins Cove: My worst trade of the year. Hope you know what you're doing......
May 28, 5:14 PM
• !Report Abuse
Add a reply...

140 characters

dindin21
$ZIOP Could this be a Intrexon takeover announcement? Really interesting.........
May 24, 8:08 PM
Reply (1)

• !Report Abuse
View all 1 replies
Barney: Short squeeze.
May 25, 7:15 AM
• !Report Abuse
Add a reply...

140 characters

Red Acre Investments
Sent out Red Acre's weekly review last night $ZIOP, $RPRX, $AMRN, $VVUS, $APPA, $UTHR, $THLD signup at http://www.redacre.com to get it.
Mar 29, 5:26 AM
Reply (3)

• !Report Abuse
View all 3 replies
Red Acre Investments: Thx for the kind words - Happy Easter to you as well.
Mar 29, 5:18 PM
• !Report Abuse
yourmama6799: Rashar for President!!!
Mar 29, 6:43 PM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$ZIOP moving like I thought it would. shorts still being stubborn, they are soon to be crushed on that one.
5/22/12
Reply (12)

• !Report Abuse
View all 12 replies
captainsaino: ^^^^CHTP
5/23/12
• !Report Abuse
StockMatusow: i agree, and CHTP is a stock that might be worth the wait for the big bucks, but not anytime soon.
5/23/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Should have an article out on $ ZIOP tomorrow. I bought some, that is my first pick, have fun
5/21/12
Reply (1)

• !Report Abuse
View all 1 replies
ttrinh17: looking forward to the article, thanks Scott!
5/21/12
• !Report Abuse
Add a reply...

140 characters

ZIOP Ziopharm Oncology Inc

ZIOP

Ziopharm Oncology Inc